Methods
T2DM, OSA
This study was registered in Science and Technology Bureau of Shenzhen Yantian District (No. 20180329). The Ethics Committee of Shenzhen Yantian People’s Hospital approved the study in accordance with the principles of the Declaration of Helsinki. It was a randomized, controlled, nonblinded clinical trial in patients with T2DM and severe OSA. The clinical trial was conducted in Shenzhen Yantian District People’s Hospital and Longyan First Hospital Affiliated to Fujian Medical University from July 2019 to September 2021. All patients visited the clinic once a month for a follow-up period of up to 3 months.